Excitement at ASCO 2014 on Incyte's new immunoonoclogy drug candidate, INCB024360 ('360),in melanoma, despite a small 'n'.
We just got our first look at the clinical activity of
immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with
Yervoy in melanoma patients
Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response
of 50%. A third patient reported stable disease so the disease control rate was 75%. The
Source: The Street